Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

Production of [89Zr]Oxinate4 and cell labeling for human use

Adriana Massicano, Charlotte Jeffers, Jennifer Bartels, Hailey Houson and Suzanne Lapi
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 468;
Adriana Massicano
1University of Alabama At Birmingham Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Jeffers
1University of Alabama At Birmingham Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Bartels
2Radiology University of Alabama- Birmingham- Medical Center Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hailey Houson
3UAB Radiology Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Lapi
4University of Alabama At Bimingham Birmingham AL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

468

Introduction: Imaging of radiolabeled White Blood Cell (WBC) is an important tool for investigation of several conditions such as infectious/inflammatory disease. The radiopharmaceuticals available for clinical WBC labeling are gamma-emitter and so are suitable only for SPECT. PET technology opens a range of options for better and more sensitive imaging techniques compared to SPECT and thus there is a need for a suitable PET tracer for cell labeling. In this work, we describe our experience in the production of [89Zr]Oxinate4 for human use and cell labeling from benchtop to bedside.

Methods: We developed a PET radiopharmaceutical suitable for human use based on oxine for WBC labeling. To do so, we optimized the benchtop chemistry varying several aspects such as buffer used to neutralize [89Zr]Oxalate, incubation time and temperature, organic solvent, glassware to perform the labeling, quality control, and filters to sterilize the final product. The optimized conditions were used to scale-up the production, which required another modification of several parameters. Briefly, the optimized production condition was: 5 mg of oxine was diluted in dichloromethane (DCM) and mixed in neutralized [89Zr]Oxalate already diluted in 5 mL of trace metal water. The mixture was incubated at room temperature for 30 minutes under vigorous agitation. The organic phase was separated, completely evaporated and suspended in 45 mL of dimethylsulfoxide (DMSO). The final formulation containing 200 µg of polysorbate 80, 12 mg of HEPES in 2 mL of 0.9% sodium chloride, was filtered into a sterile borosilicate type I vial. WBC were isolated from 120 mL of whole blood from healthy donors and labeled with 640 - 1500 µCi of [89Zr]Oxinate4 for 20 - 30 minutes at room temperature. After the incubation, the cells were washed, and the final activity recorded.

Results: [89Zr]Oxinate4 was successful produced with yield of 67 ± 14.54% (N=5) and met all acceptance criteria for human use, which include non-residual solvents (DCM <600 ppm and DMSO <5000 ppm), adequate pH (7.0), high radiochemical purity (99.67 ± 0.74%), endotoxin-free and sterility. The final radioactivity concentration was 1.93 ± 0.55 mCi/mL high enough to allow the use of less than 1 mL for WBC labeling as previous studies showed lower volumes resulted in higher cell labeling yields. Over 2.0x10^8 WBC cells were isolated from 120 ml of whole blood with a high cell viability rate (81.0 ± 3.24%). The radioactivity incorporated into the cells was 327.86 ± 116.87 µCi which resulted in a labeling efficiency of 30.87 ± 9.58% and satisfactory preservation of cell viability (75.5 ± 12.85%).

Conclusions: This study demonstrated the production results of [89Zr]Oxinate4 for human use and its application on WBC labeling. This radiopharmaceutical is suitable for theoretically any cell labeling and is already being used in different preclinical projects across UAB. The translation of this technique into human use will provide insight into several disease mechanisms, advancing and benefiting the scientific community as a whole. Acknowledgments: This project was supported by UAB Radiology. We acknowledge the support of all team members from Dr. Younger’s group, and UAB Cyclotron Facility.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Production of [89Zr]Oxinate4 and cell labeling for human use
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Production of [89Zr]Oxinate4 and cell labeling for human use
Adriana Massicano, Charlotte Jeffers, Jennifer Bartels, Hailey Houson, Suzanne Lapi
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 468;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Production of [89Zr]Oxinate4 and cell labeling for human use
Adriana Massicano, Charlotte Jeffers, Jennifer Bartels, Hailey Houson, Suzanne Lapi
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 468;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • SPECT and PET imaging of CD11b-positive immune cells in an orthotopic mouse model of glioma with Zr-89 and Lu-177 labeled Lumi804-anti-CD11b antibody
  • Bridging brain structural/functional connectivity and tau load in PSP: A [18F]PI-2620 PET/MRI study
  • N-(Maleimidoethyl)-3-(guanidinomethyl)-5-[131I]iodobenzmide ([131I]MEGMIB): A Residualizing Prosthetic Agent for Site-Specific Radioiodination of Internalizing Single Domain Antibody Fragments.
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Radiopharmacy

  • Investigation of Vape Devices as Novel Drug Delivery Systems Using Fluorine-18 Radiolabelling.
  • 68Ga-PSMA-11 prepared with the Telix kit versus a traditional synthesiser: does it matter?
  • cGMP production of [18F]3F4AP for human PET imaging
Show more Radiopharmacy

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire